# DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

> **NCT03879798** · PHASE1,PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** DS-3201b
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT03879798
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-15
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-05-02
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Due to DLTs
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879798, "DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03879798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*